IVBIY (IVBIY PINK) stock market data APIs
$39.6469
0(0%)
as of February 10, 2026
Try our APIs with
free plan!
IVBIY Financial Data Overview
Price chart is built with
Anychart
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverematinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), Dupert (fulzerasib), DOVBLERON (taletrectinib), Jaypirca (pirtobrutinib), limertinib, and SYCUME (teprotumumab N01 injection). The company is also developing three new drugs, which are under regulatory review; four assets in Phase 3 and pivotal clinical trials; and 15 molecules in early clinical stage. In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Prev. Close
39.6469
Open
39.6469
High
39.6469
Low
39.6469
52 wk Range
19.15-52
Market Cap
20 198 M
P/E Ratio
113.8974
Shares Outstanding
430 M
Revenue
11 423 M
Beta
0.229
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get IVBIY data using free add-ons & libraries
Get IVBIY Fundamental Data
IVBIY Fundamental data includes:
- Net Revenue: 11 423 M
- EBITDA: 1 302 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
IVBIY News
New
Eli Lilly Broadens Genetic Medicine Portfolio While Shares Screen As Undervalued
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics to...
Eli Lilly Uses GLP-1 Strength To Build Genetic And Oncology Portfolio
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Eli Lilly (NYSE:LLY) agreed to acquire Orna Therapeutics ...
Asian Market Stocks Trading Below Estimated Value In February 2026
As global markets grapple with volatility, driven by concerns over artificial intelligence and geopolitical tensions, investors are increasingly turning their attention to value-oriented segments that...
Eli Lilly to Buy Cell Therapy Company Orna for $2.4 Billion
Eli Lilly shares rose Monday after the Mounjaro maker said it had agreed to acquire biotechnology company Orna Therapeutics for $2.4 billion in cash. The deal value comprises an upfront payment and su...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
